DexCom(US:DXCM)2026-01-12 15:302025 Performance & 2026 Outlook - Preliminary 2025 revenue is expected to be approximately $4662 billion, representing organic growth of ~15%[31] - The active Dexcom base grew by 20%+[31] - Revenue for 2026 is projected to be between $516 billion and $525 billion, representing growth of ~11-13%[33] - Non-GAAP gross margin is expected to be ~63-64% in 2026[34] - Non-GAAP operating margin is expected to be ~22-23% in 2026[34] Market & Product Expansion - Approximately 40% of US adults have prediabetes[13] - Dexcom CGM has powered over 25 million patient years on automated insulin delivery[55] - Dexcom G7 15 Day has an updated algorithm with 80% MARD[56] - Stelo generated ~$130 million in revenue in 2025[72] Financial Expectations - The company expects to generate over $1 billion of free cash flow in 2026[89] - Adjusted EBITDA is expected to be greater than $15 billion[88]